A recent study shows the use of GLP-1 drugs can increase the risk for optic nerve damage in the first year of treatment, ...

Patients with type 2 diabetes, treated with GLP-1 receptor agonists, show a decreased risk of being diagnosed with ...

In a study on people with obesity and asthma, researchers saw “significant” improvements in the asthma scores of people who ...

Experts say there’s no evidence GLP-1s can be absorbed through the skin — and these patches don’t contain the FDA-approved ...

The popular weight-loss and diabetes drugs could play a significant role not only in disease prevention, but possibly in ...

GLP-1 patches, topical adhesive patches worn on your arm or abdomen that claim to deliver natural weight-loss revving ...

As rates of childhood obesity rise, clinicians call for increased data collection to support insurance coverage and safe use of glucagon-like peptide 1 (GLP-1) medications in children under 12 years.

Experts say people who take GLP-1 weight loss medications should stay hydrated, particularly when temperatures are high. The ...

For older patients with cancer and type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with lower all-cause mortality than dipeptidyl peptidase-4 inhibitor ...

The appetite-suppressing medications reduce consumption of processed and sugary foods, creating new risks and opportunities.

As consumers drop pounds, beauty and wellness brands are dropping products in hopes of cashing in on the rise of weight-loss drugs.

The demand for GLP-1 medications is only increasing. As employees seek better health benefits, employers who act now will set ...